Report Description
A recent market
intelligence report that is published by Data Insights Partner on the global Cardiovascular
Disease Drugs Market makes an offering of in-depth analysis of segments and
sub-segments in the regional and international Cardiovascular Disease Drugs Market.
The research also emphasizes on the impact of restraints, drivers, and macro
indicators on the regional and global Cardiovascular Disease Drugs Market over
the short as well as long period of time. A detailed presentation of forecast, trends,
and dollar values of global Cardiovascular Disease Drugs Market is offered. In
accordance with the report, the global Cardiovascular Disease Drugs Market is
projected to expand at a CAGR of 3.80 % over the period of forecast.
Market Insight, Drivers, Restraints&
Opportunity of the Market:
Cardiovascular
drugs or medicines are mainly used to cure diseases related to the heart and
circulatory system. These diseases can occur due to various reasons like high
blood pressure, aging, rheumatic fever, heart attack etc. With an increasing
number of heart diseases amongst the population across all regions, demand for
cardiovascular drug market is expected to grow considerably in the forecast
period.
Ever increasing
occurrence of heart diseases and aging population amongst all regions is the
major driving force for demand in global cardiovascular drug market. Increase
in number of patients with high blood pressure, high cholesterol levels, and
obesity, due to modern and sedentary lifestyle amongst all age groups, is yet
another factor that leads to heart diseases, further accelerating the growth of
this market.
There are strict
rules & regulations for cardiovascular drugs that can hamper the growth of
this market. Also, it has been observed that consumers taking drugs related to
cardiovascular diseases experience some kind of a side-effect, and thereby go
for other alternatives available in the market. This further hinders the growth
of cardiovascular drug market. Additionally, recent expiry of patent
exclusivity of bestselling cardiovascular drugs has led to introduction of generic
drugs by international players, which is likely to further affect the growth of
this market in the forecast period.
Due to increased
awareness of heart diseases, countries in North America specially the U.S., dominates
the cardiovascular drug market. This is followed by countries in European regions
like Germany, UK, Spain, Italy and France. However, high growth rate in the Asian
countries like Japan, China and India is predicted in the next 5 years due to
its ever increasing elderly population and urbanization.
An Indian based
company Natco Pharma has recently launched a drug ‘Vymada’ to treat congestive
heart failure. Also, several advanced drugs have been recently launched by
various companies to address issues related to heart diseases. For e.g. Pfizer
Inc. introduced a drug called ‘Eliquis’ which is far more superior in terms of
risk reduction and has the highest sales in the market. New product development
in the market will create growth opportunities for the global cardiovascular
disease drug market.
Segment Covered:
This market
intelligence report on the global Cardiovascular Disease Drugs Market encompasses
market segments based on drug class, indications, distribution channels,
stakeholders and country/regions.
In terms of drug class, the global Cardiovascular
Disease Drugs Market
is segregated into
§ Anti-hyperlipidemics
§ Anti-hypertensives
ü Diovan / Co-Diovan
ü Blopress
ü Benicar / Benicar HCT
ü Micardis / Micardis HCT
ü Aprovel / CoAprovel
ü Tekturna / Rasilez
ü Edarbi
ü Cozaar / Hyzaar
ü Norvasc
ü Exforge / Exforge HCT
ü Coversyl
ü Seloken / Toprol – XL
§ Anti-coagulants
§ Anti – dyslipemics
ü Lipitor
ü Crestor
ü Niaspan
ü TriColor / Trilipix
ü Zetia / Vytorin
ü Tredaptive
§ Anti-arrhythmics
§ Anti-Thrombotics
ü Plavix
ü Lovenox
ü Pradaxa
ü Xarelto
ü Brilique / Brilinta
ü Eliquis
§ Others
ü Cardiac glycosides
ü Antianginal drug
ü Anti – Fibrinolytic
ü Anti – Ischemic
By indications, the global Cardiovascular
Disease Drugs Market
is also classified into,
§ Hypertension
§ Hypelipidemia
§ Arterisclerosis
§ Cardiac Failure
§ Thrombosis
§ Myocardial infarction
§ Acute Coronary Artery disease
§ Cardiac Arrhythmia
§ Peripheral artery disease
§ Others
By distribution channel, the global Cardiovascular
Disease Drugs Market
is also classified into,
§ Hospitals Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ Others
By stakeholders, the global Cardiovascular
Disease Drugs Market
is also classified into,
§ Research Organization
§ Cardiovascular Drugs Manufacturer
§ Hospitals & Clinics
§ Pharmacies
§ Cardiology Associations
§ Academics & Research Institutes
§ Others
By country/region, the global Cardiovascular Disease
Drugs Market has been divided
into
§ North America (the U.S., Canada),
§ Latin America (Brazil, Mexico, Argentina and other
countries),
§ Europe (Germany, France, the U.K., Spain, Italy, Russia,
and other countries),
§ Asia Pacific (India, Japan, China, Australia and New
Zealand and other countries),
§ Middle East and Africa (GCC, South Africa, Israel and
Other countries).
Profiling of Market
Players:
This business
intelligence report offers profiling of reputed companies that are operating in
the market. Companies such as
§ Amgen Inc.
§ Baxter International Inc.
§ C.H. Boehringer Sohn AG & Co.
§ Pfizer Inc.
§ Bristol-Myers Squibb Company
§ Bayer AG
§ Janssen Pharmaceuticals Inc.
§ AstraZeneca
§ Sanofi
§ Johnson & Johnson
§ Daiichi Sankyo Inc.
§ Merck & Co. Inc
§ Gilead Sciences Inc.
§ United Therapeutics Corp
§ Sun Pharmaceuticals
§ Eli Lilly and Company
§ Takeda Pharmaceuticals
§ F. Hoffman – La Roche Ltd.
§ Novartis AG and many more
Others players have
been profiled into detail so as to offer a glimpse of the market leaders.
Moreover, parameters such as Cardiovascular Disease Drugs related investment & spending and developments by
major players of the market are tracked in this global report.
Report Highlights:
In-depth
analysis of the micro and macro indicators, market trends, and forecasts of
demand is offered by this business intelligence report. Furthermore, the report
offers a vivid picture of the factors that are steering and restraining the
growth of this market across all geographical segments. In addition to that, Growth
Matrix analysis is also provided in the report so as to share insight of the
investment areas that new or existing market players can take into consideration.
Various analytical tools such as DRO analysis, Porter's five forces analysis
has been used in this report to present a clear picture of the market. The
study focuses on the present market trends and provides market forecast from
the year 2020-2028. Emerging trends that would shape the market demand in the
years to come have been highlighted in this report. A competitive analysis in
each of the geographical segments gives an insight into market share of the
global players.
Salient Features:
Ø
This study offers
comprehensive yet detailed analysis of the Cardiovascular Disease Drugs Market, size of the market (US$ Mn), and Compound Annual Growth
Rate (CAGR (%)) for the period of forecast: 2020 – 2028, taking into account
2019 as the base year
Ø
It explains upcoming
revenue opportunities across various market segments and attractive matrix of
investment proposition for the said market
Ø
This market
intelligence report also offers pivotal insights about various market opportunities,
restraints, drivers, launch of new products, competitive market strategies of
leading market players, emerging market trends, and regional outlook
Ø
Profiling of
key market players in the world Cardiovascular
Disease Drugs Market
is done by taking into account various parameters
such as company strategies, distribution strategies, product portfolio, financial
performance, key developments, geographical presence, and company overview
Ø
Leading
market players covered this report comprise names such as Amgen Inc., Baxter
International Inc., Boehringer Sohn AG & Co, Bristol-Myers Squibb Company,
Pfizer Inc., Bayer AG, Janssen Pharmaceuticals Inc., AstraZeneca, Sanofi,
Johnson & Johnson, Daiichi Sankyo Inc., Merck & Co Inc., Gilead
Sciences Inc., United Therapeutics Corp., Sun Pharmaceuticals., Eli Lilly and
Company, Takeda Pharmaceuticals, F. Hoffman, Novartis AG and many more.
Ø
The data of
this report would allow management authorities and marketers of companies alike
to take informed decision when it comes to launch of products, government
initiatives, marketing tactics and expansion, and technical up gradation
Ø
The world
market for Cardiovascular
Disease Drugs Market
caters to the needs of various stakeholders
pertaining to this industry, namely suppliers, manufacturers, investors, and
distributors for Cardiovascular
Disease Drugs Market. The research
also caters to the rising needs of consulting and research firms, financial
analysts, and new market entrants
Ø
Research
methodologies that have been adopted for the purpose of this study have been
clearly elaborated so as to facilitate better understanding of the reports
Ø
Reports have
been made based on the guidelines as mandated by General Data Protection
Regulation
Ø
Ample number
of examples and case studies have been taken into consideration before coming
to a conclusion
Reasons to buy:
v
Identify
opportunities and plan strategies by having a strong understanding of the
investment opportunities in the Cardiovascular Disease Drugs Market
v
Identification
of key factors driving investment opportunities in the Cardiovascular Disease
Drugs Market
v
Facilitate
decision-making based on strong historic and forecast data
v
Position
yourself to gain the maximum advantage of the industry’s growth potential
v
Develop
strategies based on the latest regulatory events
v
Identify key
partners and business development avenues
v
Respond to your
competitors’ business structure, strategy and prospects
v
Identify key
strengths and weaknesses of important market participants